Up next

DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Why Biopharma’s Biggest Challenge May Not Be Geopolitics 

By
The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures on the industry’s innovation-driven model and the biotech ecosystem that supports it.

AI & Digital Transformation: Where Does the Bio/Pharma Industry Stand?

By
How AI and other digital tools are progressing across the bio/pharmaceutical industry is top of mind. Key perspectives on the use and potential of AI and other digital tools were shared at the DCAT Global Summit.

Injectables: Market & Technology Trends

By
What are key trends for injectable drugs and the related market impact? From switches from IV-administered to subcutaneous drug delivery and increased interest for home and self administration, DCAT Value Chain Insights provides the latest. 

What’s on the Minds of CEOs & Their Priorities?

By
A recent KPMG study of CEOs of large companies, including 400 US companies, found that supply-chain cost reduction and AI integration and upskilling are top priorities of CEOs. How are companies addressing these challenges?